Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 32
Filtrar
1.
BMC Pulm Med ; 20(1): 13, 2020 Jan 14.
Artículo en Inglés | MEDLINE | ID: mdl-31937286

RESUMEN

BACKGROUND: Adenosine deaminase (ADA) activity is typically elevated in patients with tuberculous pleural effusion (TPE), but low ADA has occasionally been reported in patients with TPE. The characteristics of these patients are not well-known, and erroneous exclusion of the possibility of TPE can result in a delayed diagnosis. This study investigated the characteristics of patients with TPE who had low ADA activity. METHODS: We retrospectively reviewed patients with microbiologically or pathologically confirmed TPE between 2012 to 2018 in a tertiary hospital in South Korea. Patients were categorised into two groups: high ADA (≥40 IU/L) and low ADA (< 40 IU/L). Clinical characteristics and Sequential Organ Failure Assessment (SOFA) scores were compared between groups. RESULTS: A total of 192 patients with TPE were included; 36 (18.8%) had ADA < 40 IU/L with a mean ADA activity level of 20.9 (±9.2) IU/L. Patients with low ADA were older (75.3 vs. 62.0 years, p < 0.001) and had a lower mean lymphocyte percentage (47.6% vs. 69.9%, p < 0.001) than patients with high ADA. Patients in the low ADA group had a significantly higher mean SOFA score (2.31 vs. 0.68, p < 0.001), and patients with organ dysfunction were significantly more common in the low ADA group (p < 0.001). Patients with 2 or ≥ 3 organ dysfunctions constituted 19.4 and 13.9% of the patients in the low ADA group, whereas they constituted 7.1 and 1.3% of the patients in the high ADA group (p < 0.001). Multivariate logistic regression analyses showed that older age (odds ratio = 1.030, 95% confidence interval 1.002-1.060, p = 0.038) and a higher SOFA score (odds ratio = 1.598, 95% confidence interval 1.239-2.060, p < 0.001) were significantly associated with low ADA activity in patients with TPE. CONCLUSIONS: ADA activity can be low in patients with TPE who are elderly, critically ill, and exhibit multiorgan failure. Low ADA activity cannot completely exclude the diagnosis of TPE, and physicians should exercise caution when interpreting pleural fluid exams.


Asunto(s)
Adenosina Desaminasa/metabolismo , Derrame Pleural/enzimología , Tuberculosis Pleural/enzimología , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Enfermedad Crítica , Femenino , Humanos , Lepra Multibacilar , Modelos Logísticos , Linfocitos , Masculino , Persona de Mediana Edad , Insuficiencia Multiorgánica/enzimología , Puntuaciones en la Disfunción de Órganos , Derrame Pleural/etiología , Tuberculosis Pleural/complicaciones , Tuberculosis Pleural/diagnóstico
2.
J Clin Invest ; 128(11): 5056-5072, 2018 11 01.
Artículo en Inglés | MEDLINE | ID: mdl-30320600

RESUMEN

Dysregulated intestinal epithelial apoptosis initiates gut injury, alters the intestinal barrier, and can facilitate bacterial translocation leading to a systemic inflammatory response syndrome (SIRS) and/or multi-organ dysfunction syndrome (MODS). A variety of gastrointestinal disorders, including inflammatory bowel disease, have been linked to intestinal apoptosis. Similarly, intestinal hyperpermeability and gut failure occur in critically ill patients, putting the gut at the center of SIRS pathology. Regulation of apoptosis and immune-modulatory functions have been ascribed to Thirty-eight-negative kinase 1 (TNK1), whose activity is regulated merely by expression. We investigated the effect of TNK1 on intestinal integrity and its role in MODS. TNK1 expression induced crypt-specific apoptosis, leading to bacterial translocation, subsequent septic shock, and early death. Mechanistically, TNK1 expression in vivo resulted in STAT3 phosphorylation, nuclear translocation of p65, and release of IL-6 and TNF-α. A TNF-α neutralizing antibody partially blocked development of intestinal damage. Conversely, gut-specific deletion of TNK1 protected the intestinal mucosa from experimental colitis and prevented cytokine release in the gut. Finally, TNK1 was found to be deregulated in the gut in murine and porcine trauma models and human inflammatory bowel disease. Thus, TNK1 might be a target during MODS to prevent damage in several organs, notably the gut.


Asunto(s)
Proteínas Fetales/metabolismo , Enfermedades Inflamatorias del Intestino/enzimología , Intestinos/enzimología , Insuficiencia Multiorgánica/enzimología , Traumatismo Múltiple/enzimología , Proteínas Tirosina Quinasas/metabolismo , Síndrome de Respuesta Inflamatoria Sistémica/enzimología , Animales , Modelos Animales de Enfermedad , Femenino , Proteínas Fetales/genética , Enfermedades Inflamatorias del Intestino/etiología , Enfermedades Inflamatorias del Intestino/genética , Enfermedades Inflamatorias del Intestino/patología , Interleucina-6/genética , Interleucina-6/metabolismo , Intestinos/patología , Ratones , Insuficiencia Multiorgánica/etiología , Insuficiencia Multiorgánica/genética , Insuficiencia Multiorgánica/patología , Traumatismo Múltiple/complicaciones , Traumatismo Múltiple/genética , Traumatismo Múltiple/patología , Proteínas Tirosina Quinasas/genética , Factor de Transcripción STAT3/genética , Factor de Transcripción STAT3/metabolismo , Porcinos , Síndrome de Respuesta Inflamatoria Sistémica/etiología , Síndrome de Respuesta Inflamatoria Sistémica/patología , Factor de Transcripción ReIA/genética , Factor de Transcripción ReIA/metabolismo , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/metabolismo
3.
Shock ; 45(5): 525-33, 2016 May.
Artículo en Inglés | MEDLINE | ID: mdl-26863124

RESUMEN

Severe hemorrhage can lead to global ischemia and hemorrhagic shock (HS), resulting in multiple organ failure (MOF) and death. Restoration of blood flow and re-oxygenation is associated with an exacerbation of tissue injury and inflammatory response. The neuronal nitric oxide synthase (nNOS) has been implicated in vascular collapse and systemic inflammation of septic shock; however, the role of nNOS in HS is poorly understood. The aim of this study was to evaluate the role of nNOS in the MOF associated with HS.Rats were subjected to HS under anesthesia. Mean arterial pressure was reduced to 30  mmHg for 90  min, followed by resuscitation with shed blood. Rats were randomly treated with two chemically distinct nNOS inhibitors [ARL 17477 (1 mg/kg) and 7-nitroindazol (5 mg/kg)] or vehicle upon resuscitation. Four hours later, parameters of organ injury and dysfunction were assessed.HS was associated with MOF development. Inhibition of nNOS activity at resuscitation protected rats against the MOF and vascular dysfunction. In addition, treatment of HS rats with nNOS inhibitors attenuated neutrophil infiltration into target organs and decreased the activation of NF-κB, iNOS expression, NO production, and nitrosylation of proteins. Furthermore, nNOS inhibition also reduced the levels of pro-inflammatory cytokines TNF-α and IL-6 in HS rats.In conclusion, two distinct inhibitors of nNOS activity reduced the MOF, vascular dysfunction, and the systemic inflammation associated with HS. Thus, nNOS inhibitors may be useful as an adjunct therapy before fluids and blood administration in HS patients to avoid the MOF associated with reperfusion injury during resuscitation.


Asunto(s)
Insuficiencia Multiorgánica/etiología , Insuficiencia Multiorgánica/metabolismo , Óxido Nítrico Sintasa de Tipo I/metabolismo , Choque Hemorrágico/complicaciones , Choque Hemorrágico/metabolismo , Amidinas/farmacología , Animales , Indazoles/farmacología , Interleucina-6/metabolismo , Masculino , Insuficiencia Multiorgánica/enzimología , FN-kappa B/metabolismo , Infiltración Neutrófila/efectos de los fármacos , Óxido Nítrico Sintasa de Tipo I/antagonistas & inhibidores , Ratas , Ratas Wistar , Factor de Necrosis Tumoral alfa/metabolismo
4.
Exp Biol Med (Maywood) ; 240(8): 1039-49, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-26283706

RESUMEN

In this minireview, we cover the discovery of the human erythrocyte α spectrin E2/E3 ubiquitin conjugating/ligating enzymatic activity and the specific cysteines involved. We then discuss the consequences when this activity is partially inhibited in sickle cell disease and the possibility that the same attenuation is occurring in multiple organ dysfunction syndrome. We finish by discussing the reasons for believing that nonerythroid α spectrin isoforms (I and II) also have this activity and the importance of testing this hypothesis. If correct, this would suggest that the nonerythroid spectrin isoforms play a major role in protein ubiquitination in all cell types. This would open new fields in experimental biology focused on uncovering the impact that this enzymatic activity has upon protein-protein interactions, protein turnover, cellular signaling, and many other functions impacted by spectrin, including DNA repair.


Asunto(s)
Anemia de Células Falciformes/enzimología , Reparación del ADN , Eritrocitos/enzimología , Insuficiencia Multiorgánica/enzimología , Transducción de Señal , Espectrina/metabolismo , Ubiquitina-Proteína Ligasas/metabolismo , Ubiquitinación , Animales , Humanos
5.
FASEB J ; 29(9): 3737-49, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25993992

RESUMEN

Serum- and glucocorticoid-regulated kinase (SGK)1 is associated with several important pathologic conditions and plays a modulatory role in adaptive immune responses. However, the involvement and functional role of SGK1 in innate immune responses remain entirely unknown. In this study, we establish that SGK1 is a novel and potent negative regulator of TLR-induced inflammation. Pharmacologic inhibition of SGK1 or suppression by small interfering RNA enhances proinflammatory cytokine (TNF, IL-12, and IL-6) production in TLR-engaged monocytes, a result confirmed in Cre-loxP-mediated SGK1-deficient cells. SGK1 inhibition or gene deficiency results in increased phosphorylation of IKK, IκBα, and NF-κB p65 in LPS-stimulated cells. Enhanced NF-κB p65 DNA binding also occurs upon SGK1 inhibition. The subsequent enhancement of proinflammatory cytokines is dependent on the phosphorylation of TGF-ß-activated kinase 1 (TAK1), as confirmed by TAK1 gene silencing. In vivo relevance was established in a murine endotoxin model, in which we found that SGK1 inhibition aggravates the severity of multiple organ damage and enhances the inflammatory response by heightening both proinflammatory cytokine levels and neutrophil infiltration. These findings have identified an anti-inflammatory function of SGK1, elucidated the underlying intracellular mechanisms, and establish, for the first time, that SGK1 holds potential as a novel target for intervention in the control of inflammatory diseases.


Asunto(s)
Proteínas Inmediatas-Precoces/antagonistas & inhibidores , Proteínas Inmediatas-Precoces/metabolismo , Lipopolisacáridos/toxicidad , Insuficiencia Multiorgánica/enzimología , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Proteínas Serina-Treonina Quinasas/metabolismo , Receptores Toll-Like/metabolismo , Animales , Citocinas/genética , Citocinas/metabolismo , Femenino , Humanos , Quinasa I-kappa B/genética , Quinasa I-kappa B/metabolismo , Proteínas Inmediatas-Precoces/genética , Inflamación/inducido químicamente , Inflamación/enzimología , Inflamación/genética , Quinasas Quinasa Quinasa PAM/genética , Quinasas Quinasa Quinasa PAM/metabolismo , Masculino , Ratones , Ratones Transgénicos , Insuficiencia Multiorgánica/inducido químicamente , Insuficiencia Multiorgánica/genética , Proteínas Serina-Treonina Quinasas/genética , ARN Interferente Pequeño/genética , Receptores Toll-Like/genética , Factor de Transcripción ReIA/genética , Factor de Transcripción ReIA/metabolismo
6.
Dis Model Mech ; 6(4): 1031-42, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23649820

RESUMEN

Nuclear factor κB (NF-κB) plays a pivotal role in sepsis. Activation of NF-κB is initiated by the signal-induced ubiquitylation and subsequent degradation of inhibitors of kappa B (IκBs) primarily via activation of the IκB kinase (IKK). This study was designed to investigate the effects of IKK inhibition on sepsis-associated multiple organ dysfunction and/or injury (MOD) and to elucidate underlying signaling mechanisms in two different in vivo models: male C57BL/6 mice were subjected to either bacterial cell wall components [lipopolysaccharide and peptidoglycan (LPS/PepG)] or underwent cecal ligation and puncture (CLP) to induce sepsis-associated MOD. At 1 hour after LPS/PepG or CLP, mice were treated with the IKK inhibitor IKK 16 (1 mg/kg body weight). At 24 hours, parameters of organ dysfunction and/or injury were assessed in both models. Mice developed a significant impairment in systolic contractility (echocardiography), and significant increases in serum creatinine, serum alanine aminotransferase and lung myeloperoxidase activity, thus indicating cardiac dysfunction, renal dysfunction, hepatocellular injury and lung inflammation, respectively. Treatment with IKK 16 attenuated the impairment in systolic contractility, renal dysfunction, hepatocellular injury and lung inflammation in LPS/PepG-induced MOD and in polymicrobial sepsis. Compared with mice that were injected with LPS/PepG or underwent CLP, immunoblot analyses of heart and liver tissues from mice that were injected with LPS/PepG or underwent CLP and were also treated with IKK 16 revealed: (1) significant attenuation of the increased phosphorylation of IκBα; (2) significant attenuation of the increased nuclear translocation of the NF-κB subunit p65; (3) significant attenuation of the increase in inducible nitric oxide synthase (iNOS) expression; and (4) a significant increase in the phosphorylation of Akt and endothelial nitric oxide synthase (eNOS). Here, we report for the first time that delayed IKK inhibition reduces MOD in experimental sepsis. We suggest that this protective effect is (at least in part) attributable to inhibition of inflammation through NF-κB, the subsequent decrease in iNOS expression and the activation of the Akt-eNOS survival pathway.


Asunto(s)
Quinasa I-kappa B/antagonistas & inhibidores , Insuficiencia Multiorgánica/complicaciones , Insuficiencia Multiorgánica/enzimología , Sepsis/complicaciones , Sepsis/enzimología , Animales , Ciego/efectos de los fármacos , Ciego/patología , Ciego/fisiopatología , Pruebas de Función Cardíaca/efectos de los fármacos , Quinasa I-kappa B/metabolismo , Proteínas I-kappa B/metabolismo , Riñón/efectos de los fármacos , Riñón/patología , Riñón/fisiopatología , Ligadura , Lipopolisacáridos/administración & dosificación , Lipopolisacáridos/farmacología , Hígado/efectos de los fármacos , Hígado/enzimología , Hígado/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Insuficiencia Multiorgánica/patología , Insuficiencia Multiorgánica/fisiopatología , Miocardio/enzimología , Miocardio/patología , Inhibidor NF-kappaB alfa , Óxido Nítrico Sintasa de Tipo II/metabolismo , Óxido Nítrico Sintasa de Tipo III/metabolismo , Peptidoglicano/administración & dosificación , Peptidoglicano/farmacología , Neumonía/complicaciones , Neumonía/patología , Neumonía/fisiopatología , Inhibidores de Proteínas Quinasas/farmacología , Proteínas Proto-Oncogénicas c-akt/metabolismo , Punciones , Sepsis/fisiopatología , Transducción de Señal/efectos de los fármacos , Factor de Transcripción ReIA/metabolismo
7.
J Neurol Sci ; 326(1-2): 24-8, 2013 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-23343605

RESUMEN

Coenzyme Q10 (ubiquinone or CoQ10) serves as a redox carrier in the mitochondrial oxidative phosphorylation system. The reduced form of this lipid-soluble antioxidant (ubiquinol) is involved in other metabolic processes as well, such as preventing reactive oxygen species (ROS) induced damage from the mitochondrial membrane. Primary coenzyme Q10 deficiency is a rare, autosomal recessive disorder, often presenting with neurological and/or muscle involvement. Until now, five patients from four families have been described with primary coenzyme Q10 deficiency due to mutations in COQ2 encoding para-hydroxybenzoate polyprenyl transferase. Interestingly, four of these patients showed a distinctive renal involvement (focal segmental glomerular sclerosis, crescentic glomerulonephritis, nephrotic syndrome), which is only very rarely seen in correlation with mitochondrial disorders. The fifth patient deceases due to infantile multi organ failure, also with renal involvement. Here we report a novel homozygous mutation in COQ2 (c.905C>T, p.Ala302Val) in a dizygotic twin from consanguineous Turkish parents. The children were born prematurely and died at the age of five and six months, respectively, after an undulating disease course involving apneas, seizures, feeding problems and generalized edema, alternating with relative stable periods without the need of artificial ventilation. There was no evidence for renal involvement. We would like to raise awareness for this potentially treatable disorder which could be under diagnosed in patients with fatal neonatal or infantile multi-organ disease.


Asunto(s)
Transferasas Alquil y Aril/deficiencia , Transferasas Alquil y Aril/genética , Enfermedades en Gemelos/genética , Enfermedades Metabólicas/genética , Insuficiencia Multiorgánica/genética , Mutación/genética , Secuencia de Aminoácidos , Enfermedades en Gemelos/diagnóstico , Enfermedades en Gemelos/enzimología , Resultado Fatal , Femenino , Homocigoto , Humanos , Lactante , Masculino , Enfermedades Metabólicas/diagnóstico , Enfermedades Metabólicas/enzimología , Datos de Secuencia Molecular , Insuficiencia Multiorgánica/diagnóstico , Insuficiencia Multiorgánica/enzimología
8.
J Diabetes Complications ; 27(1): 29-33, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-22906552

RESUMEN

BACKGROUND: Type-1 diabetes causes serious complications. Detailed molecular pathways of type-1 diabetes-mediated organ dysfunction are not completely understood. Significantly depressed (Na(+)+K(+))-ATPase (NKA) activity has been found in erythrocytes, pancreatic ß-cells, nerve cells, and muscle tissues of type-1 diabetic patients and rodent animal models. The characteristics of NKA in the development of the type-1 diabetes-mediated complications remain obscure. Here we investigated whether alterations of NKA activity in heart, kidney, and pancreas of type-1 diabetic mice occur simultaneously and whether depressed NKA activity is a universal phenomenon in major organs in the development of type-1 diabetes-induced complications. METHODS: Female non-obese diabetic (NOD) and non-obese resistant mice were used for the study. Mice blood glucose was monitored and ouabain-sensitive NKA activity was determined. RESULTS: Experimental results reveal that reduced NKA activity correlates with the progression of elevated blood glucose along with marked altered NKA apparent Na(+) affinity in all three organs of NOD mice. No significant changes of NKA protein expression were detected while the enzyme activity was reduced in tested mice, suggesting an inactive form of NKA might present in different tissues of the NOD mice. CONCLUSION: Our study suggests that concurrent impairment of NKA function in multi-organ may serve as one of the molecular pathways participating in and contributing to the mechanism of type-1 diabetes-induced complications in NOD mice. A successful protection of NKA function from injury might offer a good intervention for controlling the progression of the disease.


Asunto(s)
Diabetes Mellitus Tipo 1/enzimología , Insuficiencia Multiorgánica/enzimología , ATPasa Intercambiadora de Sodio-Potasio/metabolismo , Animales , Glucemia/análisis , Glucemia/metabolismo , Diabetes Mellitus Tipo 1/complicaciones , Femenino , Riñón/enzimología , Ratones , Ratones Endogámicos NOD , Insuficiencia Multiorgánica/etiología , Miocardio/enzimología , Páncreas/enzimología , ATPasa Intercambiadora de Sodio-Potasio/genética
9.
Pak J Pharm Sci ; 25(1): 175-81, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22186327

RESUMEN

The plants and their functional ingredients hold potential to cure various maladies and number of plants hold therapeutic potential. The present research was designed study the health promoting potential of black cumin (Nigella sativa) fixed oil (BCFO) and essential oil (BCEO) against oxidative stress with special reference to multiple organ toxicity. For the purpose, thirty rats (Strain: Sprague Dawley) were procured and divided into three groups (10 rats/group). The groups were fed on their respective diets i.e. D1 (control), D2 (BCFO @ 4.0%) and D3 (BCEO @ 0.30%) for a period of 56 days. Mild oxidative stress was induced with the help of potassium bromate injection @ 45 mg/Kg body weight. Furthermore, the levels of cardiac and liver enzymes were assayed. The results indicated that oxidative stress increased the activities of cardiac and liver enzymes. However, supplementation of BCFO and BCEO was effective in reducing the abnormal values of enzymes. Elevated levels of lactate dehydrogenase (LDH), CPK and CPK-MB were reduced from 456 to 231, 176 to 122 and 45 to 36mg/dL, respectively. Similarly, liver enzymes were also reduced. However, the results revealed that BCEO supplementation @ 0.30% is more effectual in ameliorating the multiple organ toxicity in oxidative stressed animal modelling. In the nutshell, it can be assumed that black cumin essential oil is more effective in reducing the extent of potassium bromate induced multiple organ toxicity (cardiac and liver enzymes imbalance) that will ultimately helpful in reducing the extent of myocardial and liver necrosis.


Asunto(s)
Insuficiencia Multiorgánica/dietoterapia , Miocardio/enzimología , Nigella sativa/química , Estrés Oxidativo/efectos de los fármacos , Fitoterapia/métodos , Aceites de Plantas/uso terapéutico , Animales , Biomarcadores/sangre , Bromatos , Creatina/sangre , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos/métodos , Evaluación Preclínica de Medicamentos/estadística & datos numéricos , Corazón/efectos de los fármacos , Humanos , Riñón/efectos de los fármacos , Riñón/metabolismo , Insuficiencia Multiorgánica/inducido químicamente , Insuficiencia Multiorgánica/enzimología , Aceites de Plantas/farmacología , Ratas , Ratas Sprague-Dawley , Urea/sangre , Ácido Úrico/sangre
10.
Pancreas ; 40(7): 1097-102, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21926545

RESUMEN

OBJECTIVES: Complement activation may play a prominent role in acute pancreatitis (AP). Mannan-binding lectin (MBL) and MBL-associated serine protease 2 (MASP-2) participate in complement activation. The objective of the present study was to evaluate the role of MBL and MASP-2 as markers in AP with regard to etiology, inflammatory activity, severity, and development of multiorgan failure. METHODS: Sixty patients with AP were included. All patients were diagnosed and treated according to a standardized regimen. Blood samples were obtained immediately on admission and again on days 1, 2, and 14. RESULTS: Both MBL (P < 0.001) and MASP-2 (P = 0.002) levels changed significantly over time, but without any significant relation to severity, multiorgan failure, or mortality. We found significantly higher levels of MBL (P = 0.04) in alcohol- than in gallstone-induced AP, but no significant difference in MASP-2 levels. CONCLUSIONS: The MBL and MASP-2 acted as acute-phase reactants, but overall, they were not markers for severity, multiorgan failure, nor for mortality in AP. Our results suggest that MBL and MASP-2 play only a minor role in the inflammatory response in AP.


Asunto(s)
Activación de Complemento , Lectina de Unión a Manosa/sangre , Serina Proteasas Asociadas a la Proteína de Unión a la Manosa/metabolismo , Insuficiencia Multiorgánica/etiología , Pancreatitis Alcohólica/enzimología , Pancreatitis/enzimología , Enfermedad Aguda , Adulto , Anciano , Anciano de 80 o más Años , Proteína C-Reactiva/metabolismo , Estudios de Casos y Controles , Femenino , Cálculos Biliares/complicaciones , Humanos , Mediadores de Inflamación/sangre , Interleucina-6/sangre , Masculino , Persona de Mediana Edad , Insuficiencia Multiorgánica/enzimología , Insuficiencia Multiorgánica/inmunología , Insuficiencia Multiorgánica/mortalidad , Pancreatitis/etiología , Pancreatitis/inmunología , Pancreatitis/mortalidad , Pancreatitis Alcohólica/etiología , Pancreatitis Alcohólica/inmunología , Pancreatitis Alcohólica/mortalidad , Pronóstico , Estudios Prospectivos , Medición de Riesgo , Factores de Riesgo , Índice de Severidad de la Enfermedad , Factores de Tiempo , Adulto Joven
11.
Am J Respir Crit Care Med ; 182(6): 762-73, 2010 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-20508212

RESUMEN

RATIONALE: Sepsis is a leading cause of death in the intensive care unit, characterized by a systemic inflammatory response (SIRS) and bacterial infection, which can often induce multiorgan damage and failure. Leukocyte recruitment, required to limit bacterial spread, depends on phosphoinositide-3 kinase γ (PI3Kγ) signaling in vitro; however, the role of this enzyme in polymicrobial sepsis has remained unclear. OBJECTIVES: This study aimed to determine the specific role of the kinase activity of PI3Kγ in the pathogenesis of sepsis and multiorgan damage. METHODS: PI3Kγ wild-type, knockout, and kinase-dead mice were exposed to cecal ligation and perforation-induced sepsis and assessed for survival; pulmonary, hepatic, and cardiovascular damage; coagulation derangements; systemic inflammation; bacterial spread; and neutrophil recruitment. Additionally, wild-type mice were treated either before or after the onset of sepsis with a PI3Kγ inhibitor and assessed for survival, neutrophil recruitment, and bacterial spread. MEASUREMENTS AND MAIN RESULTS: Both genetic and pharmaceutical PI3Kγ kinase inhibition significantly improved survival, reduced multiorgan damage, and limited bacterial decompartmentalization, while modestly affecting SIRS. Protection resulted from both neutrophil-independent mechanisms, involving improved cardiovascular function, and neutrophil-dependent mechanisms, through reduced susceptibility to neutrophil migration failure during severe sepsis by maintaining neutrophil surface expression of the chemokine receptor, CXCR2. Furthermore, PI3Kγ pharmacological inhibition significantly decreased mortality and improved neutrophil migration and bacterial control, even when administered during established septic shock. CONCLUSIONS: This study establishes PI3Kγ as a key molecule in the pathogenesis of septic infection and the transition from SIRS to organ damage and identifies it as a novel possible therapeutic target.


Asunto(s)
Insuficiencia Multiorgánica/enzimología , Infiltración Neutrófila/fisiología , Fosfatidilinositol 3-Quinasas/fisiología , Sepsis/enzimología , Animales , Quimiotaxis de Leucocito , Fosfatidilinositol 3-Quinasa Clase Ib , Modelos Animales de Enfermedad , Inhibidores Enzimáticos/farmacología , Isoenzimas/antagonistas & inhibidores , Isoenzimas/fisiología , Estimación de Kaplan-Meier , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Insuficiencia Multiorgánica/prevención & control , Inhibidores de las Quinasa Fosfoinosítidos-3 , Sepsis/prevención & control , Transducción de Señal/efectos de los fármacos , Síndrome de Respuesta Inflamatoria Sistémica/enzimología , Síndrome de Respuesta Inflamatoria Sistémica/prevención & control
12.
Shock ; 34(5): 442-9, 2010 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-20386497

RESUMEN

Phosphoinositide-3 kinases (PI3Ks) are critical regulatory proteins in the immunologic defense system against sepsis. The PI3K mechanism helps modulate cellular survival, innate and adaptive immunities, inflammation, nuclear factor-κB transcription, and may, in turn, play a protective role in sepsis. Animal studies confirm its role in the prevention of organ dysfunction and improvement of survival outcomes. Further advances in the understanding of this key immunomodulatory pathway may provide valuable insights into the manipulation of cellular function for therapeutic treatment of sepsis and other inflammatory diseases.


Asunto(s)
Fosfatidilinositol 3-Quinasas/fisiología , Sepsis/enzimología , Inmunidad Adaptativa , Animales , Supervivencia Celular , Activación Enzimática , Regulación de la Expresión Génica/fisiología , Humanos , Inmunidad Innata , Inflamación/enzimología , Ratones , Ratones Noqueados , Modelos Biológicos , Insuficiencia Multiorgánica/enzimología , Insuficiencia Multiorgánica/etiología , Insuficiencia Multiorgánica/prevención & control , FN-kappa B/fisiología , Peritonitis/enzimología , Peritonitis/inmunología , Peritonitis/fisiopatología , Fosfatidilinositol 3-Quinasas/inmunología , Isoformas de Proteínas/fisiología , Proteínas Quinasas/fisiología , Proteínas Proto-Oncogénicas c-akt/fisiología , Sepsis/complicaciones , Sepsis/inmunología , Sepsis/fisiopatología , Transducción de Señal/fisiología
13.
Pharmacol Res ; 61(2): 175-87, 2010 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-19819333

RESUMEN

PD98059 (MEK1 Inhibitor) has been shown to act in vivo as a highly selective inhibitor of MEK1 activation and the MAP kinase cascade. In the present study, we have investigated the effects of PD98059, on the development of non-septic shock caused by zymosan in mice. Mice received either intraperitoneally zymosan (500mg/kg, administered i.p. as a suspension in saline) or vehicle (0.25ml/mouse saline). PD98059 (10mg/kg) was administered 1 and 6h after zymosan administration i.p. Organ failure and systemic inflammation in mice was assessed 18h after administration of zymosan and/or PD98059. Treatment of mice with PD98059 attenuated the peritoneal exudation and the migration of polymorphonuclear cells caused by zymosan. PD98059 also attenuated the lung, liver and pancreatic injury and renal dysfunction caused by zymosan as well as the increase of TNF-alpha and IL-1beta plasma levels caused by zymosan. Immunohistochemical analysis for inducible nitric oxide synthase (iNOS), nitrotyrosine, poly(ADP-ribose) (PAR), ICAM-1, P-selectin, Bax, Bcl-2 and FAS-ligand revealed positive staining in pancreatic and intestinal tissue obtained from zymosan-injected mice. The degree of staining for nitrotyrosine, iNOS, PAR, ICAM-1, P-selectin, Bax, Bcl-2 and FAS-ligand were markedly reduced in tissue sections obtained from zymosan-injected mice, which had received PD98059. Moreover treatment of mice with PD98059 (10mg/kg) attenuated the NF-kappaB activation and mitogen-activated protein kinases (MAPK) expression induced by zymosan injection. In addition, administration of zymosan caused a severe illness in the mice characterized by a systemic toxicity, significant loss of body weight and a 60% of mortality at the end of observation period. Treatment with PD98059 significantly reduced the development of systemic toxicity, the loss in body weight and the mortality (20%) caused by zymosan. This study provides evidence that PD98059 attenuates the degree of zymosan-induced non-septic shock in mice.


Asunto(s)
Flavonoides/farmacología , Proteínas Quinasas Activadas por Mitógenos/antagonistas & inhibidores , Insuficiencia Multiorgánica/prevención & control , Inhibidores de Proteínas Quinasas/farmacología , Síndrome de Respuesta Inflamatoria Sistémica/prevención & control , Enfermedad Aguda , Animales , Apoptosis/efectos de los fármacos , Moléculas de Adhesión Celular/metabolismo , Citocinas/metabolismo , Proteína Ligando Fas/metabolismo , Proteínas I-kappa B/metabolismo , Mediadores de Inflamación/metabolismo , Masculino , Ratones , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Insuficiencia Multiorgánica/inducido químicamente , Insuficiencia Multiorgánica/enzimología , Insuficiencia Multiorgánica/inmunología , Insuficiencia Multiorgánica/patología , Inhibidor NF-kappaB alfa , Infiltración Neutrófila/efectos de los fármacos , Óxido Nítrico/metabolismo , Óxido Nítrico Sintasa de Tipo II/metabolismo , Peritonitis/enzimología , Peritonitis/prevención & control , Fosforilación , Poli(ADP-Ribosa) Polimerasas/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Síndrome de Respuesta Inflamatoria Sistémica/inducido químicamente , Síndrome de Respuesta Inflamatoria Sistémica/enzimología , Síndrome de Respuesta Inflamatoria Sistémica/inmunología , Síndrome de Respuesta Inflamatoria Sistémica/patología , Factores de Tiempo , Factor de Transcripción ReIA/metabolismo , Tirosina/análogos & derivados , Tirosina/metabolismo , Zimosan , Proteína X Asociada a bcl-2/metabolismo , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
14.
Anesteziol Reanimatol ; (2): 52-6, 2009.
Artículo en Ruso | MEDLINE | ID: mdl-19514442

RESUMEN

The aim of the investigation was to study oxidative stress and hepatic monooxygenase function (HMF) in coronary heart disease (CHD) patients with multiple organ dysfunction (MOD) after myocardial revascularization. Twenty-seven CHD patients with signs of MOD and 38 patients with an uncomplicated postoperative period were examined. The intensity of MOD was rated by the SOFA scale; oxidative stress was estimated from the values of malondialdehyde, conjugate trienes, ceruplasmin, and catalase, and HMF was evaluated from antipyrine pharmacokinetic data. On postoperative day 1, the study group showed significant signs of MOD, as well as activated lipid peroxidation (LPO) and a 1.5-fold reduction in HMF. The control group displayed an insignificant HMF suppression under less marked oxidative stress. On days 3-4 after surgery, the total MOD index was noticeably lowered. Both groups exhibited a high LPO rate and enhanced HMF. On days 10-12 postoperatively, the severity of MOD corresponded to the previous period. There was a decrease in LPO activity in both groups. HMF was found to substantially reduce in the study group and to be in line with the baseline values in the control one. Correlation analysis revealed direct and inverse relationships of the indices of MOD with LPO rates and HMF. Therefore, MOD in patients with CHD is attended by increased oxidative stress and leads to a more significant HMF reduction as compared with those with an uncomplicated postoperative period. At the same time, LPO activation is one of the cardinal causes of HMF suppression. Reduced HMF may enhance the sensitivity of CHD patients to drug therapy.


Asunto(s)
Citocromos/metabolismo , Peroxidación de Lípido , Insuficiencia Multiorgánica/etiología , Isquemia Miocárdica/cirugía , Revascularización Miocárdica , Complicaciones Posoperatorias/etiología , Xenobióticos/metabolismo , Humanos , Pruebas de Función Hepática , Microsomas Hepáticos/enzimología , Microsomas Hepáticos/metabolismo , Persona de Mediana Edad , Insuficiencia Multiorgánica/enzimología , Insuficiencia Multiorgánica/metabolismo , Isquemia Miocárdica/enzimología , Isquemia Miocárdica/metabolismo , Revascularización Miocárdica/métodos , Estrés Oxidativo , Complicaciones Posoperatorias/enzimología , Complicaciones Posoperatorias/metabolismo , Índice de Severidad de la Enfermedad , Xenobióticos/farmacocinética
15.
Clin Sci (Lond) ; 112(9): 499-506, 2007 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-17117920

RESUMEN

Patients with sepsis in the ICU (intensive care unit) are characterized by skeletal muscle wasting. This leads to muscle dysfunction that also influences the respiratory capacity, resulting in prolonged mechanical ventilation. Catabolic conditions are associated with a general activation of the ubiquitin-proteasome pathway in skeletal muscle. The aim of the present study was to measure the proteasome proteolytic activity in both respiratory and leg muscles from ICU patients with sepsis and, in addition, to assess the variation of proteasome activity between individuals and between duplicate leg muscle biopsy specimens. When compared with a control group (n=10), patients with sepsis (n=10) had a 30% (P<0.05) and 45% (P<0.05) higher proteasome activity in the respiratory and leg muscles respectively. In a second experiment, ICU patients with sepsis (n=17) had a 55% (P<0.01) higher proteasome activity in the leg muscle compared with a control group (n=10). The inter-individual scatter of proteasome activity was larger between the patients with sepsis than the controls. We also observed a substantial intra-individual difference in activity between duplicate biopsies in several of the subjects. In conclusion, the proteolytic activity of the proteasome was higher in skeletal muscle from patients with sepsis and multiple organ failure compared with healthy controls. It was shown for the first time that respiratory and leg muscles were affected similarly. Furthermore, the variation in proteasome activity between individuals was more pronounced in the ICU patients for both muscle types, whereas the intra-individual variation between biopsies was similar for ICU patients and controls.


Asunto(s)
Músculo Esquelético/enzimología , Complejo de la Endopetidasa Proteasomal/metabolismo , Sepsis/enzimología , Anciano , Biopsia , Caquexia/enzimología , Femenino , Humanos , Pierna , Masculino , Persona de Mediana Edad , Insuficiencia Multiorgánica/enzimología , Músculos Respiratorios/enzimología
16.
Br J Pharmacol ; 146(4): 498-505, 2005 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16100527

RESUMEN

Hydrogen sulfide (H2S) is a naturally occurring gaseous transmitter, which may play important roles in normal physiology and disease. Here, we investigated the role of H2S in the organ injury caused by severe endotoxemia in the rat. Male Wistar rats were subjected to acute endotoxemia (Escherichia coli lipopolysaccharide (LPS) 6 mg kg(-1) intravenously (i.v.) for 6 h) and treated with vehicle (saline, 1 ml kg(-1) i.v.) or DL-propargylglycine (PAG, 10-100 mg kg(-1) i.v.), an inhibitor of the H2S-synthesizing enzyme cystathionine-gamma-lyase (CSE). PAG was administered either 30 min prior to or 60 min after the induction of endotoxemia. Endotoxemia resulted in circulatory failure (hypotension and tachycardia) and an increase in serum levels of alanine aminotransferase and aspartate aminotransferase (markers for hepatic injury), lipase (indicator of pancreatic injury) and creatine kinase (indicator of neuromuscular injury). In the liver, endotoxemia induced a significant increase in the myeloperoxidase (MPO) activity, and in the expression and activity of the H2S-synthesizing enzymes CSE and cystathionine-beta-synthase. Administration of PAG either prior to or after the injection of LPS dose-dependently reduced the hepatocellular, pancreatic and neuromuscular injury caused by endotoxemia, but not the circulatory failure. Pretreatment of rats with PAG abolished the LPS-induced increase in the MPO activity and in the formation of H2S and in the liver. These findings support the view that an enhanced formation of H2S contributes to the pathophysiology of the organ injury in endotoxemia. We propose that inhibition of H2S synthesis may be a useful therapeutic strategy against the organ injury associated with sepsis and shock.


Asunto(s)
Alquinos/farmacología , Quimiotaxis de Leucocito/efectos de los fármacos , Cistationina gamma-Liasa/antagonistas & inhibidores , Endotoxemia/prevención & control , Glicina/análogos & derivados , Sulfuro de Hidrógeno/metabolismo , Hígado/efectos de los fármacos , Insuficiencia Multiorgánica/prevención & control , ARN Mensajero/metabolismo , Alanina Transaminasa/sangre , Alquinos/administración & dosificación , Análisis de Varianza , Animales , Presión Sanguínea/efectos de los fármacos , Creatina Quinasa/sangre , Cistationina betasintasa/genética , Cistationina betasintasa/metabolismo , Cistationina gamma-Liasa/genética , Cistationina gamma-Liasa/metabolismo , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Endotoxemia/inducido químicamente , Endotoxemia/enzimología , Endotoxemia/fisiopatología , Glicina/administración & dosificación , Glicina/farmacología , Frecuencia Cardíaca/efectos de los fármacos , Lipasa/sangre , Lipopolisacáridos , Hígado/enzimología , Hígado/fisiopatología , Masculino , Insuficiencia Multiorgánica/enzimología , Insuficiencia Multiorgánica/fisiopatología , Páncreas/efectos de los fármacos , Páncreas/enzimología , Páncreas/fisiopatología , Peroxidasa/metabolismo , Ratas , Ratas Wistar , Factores de Tiempo
17.
Med Hypotheses ; 63(6): 1057-64, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15504576

RESUMEN

The pathogenesis of preeclampsia stems from aberrant changes at the placental interface. The trophoblastic endovascular invasion of tonic spiral arteries that converts them to passive conduits falters. Uteroplacental insufficiency and fetoplacental hypoxemia result. Secondary maternal oxidative stress and an excessive inflammatory response to pregnancy generate the clinical syndrome of preeclampsia. Current treatment focuses on preventing seizures, controlling hypertension, preserving renal function and delivering the baby. We propose that the pathophysiological changes induced by preeclampsia in the placenta parallel those caused by persistent hypoxemia in the lungs at high altitude or with chronic obstructive pulmonary disease. Unrelenting pulmonary hypoxic vasoconstriction induces pulmonary hypertension and cor pulmonale. Inhalation of nitric oxide and phosphodiesterase-5 inhibitors opposes pulmonary hypoxic vasoconstriction, alleviates pulmonary hypertension and improves systemic oxygenation. Notably nitric oxide donor therapy also counters hypoxemic fetoplacental vasoconstriction, a biological response analogous to pulmonary hypoxic vasoconstriction. Fetal oxygenation and nutrition improve. Placental upstream resistance to umbilical arterial blood flow decreases. Fetal right ventricular impedance falls. Heart failure (cor placentale) is avoided. Emergency preterm delivery can be postponed. Other than low dose aspirin and antioxidants vitamins C and E no available therapy specifically targets the underlying disease profile. We hypothesize that, like nitric oxide donation, pharmacological inhibition of placental phosphodiesterase-5 will also protect the fetus but for a longer time. Biological availability of guanosine 3'5'-cyclic monophosphate is boosted due to slowed hydrolysis. Adenosine 3'5'-cyclic monphosphate levels increase in parallel. Cyclic nucleotide accumulation dilates intact tonic spiral arteries and counters hypoxemic fetoplacental vasoconstriction. Intervillous and intravillous perfusion pick up. Maternal to fetal placental circulatory matching improves. Enhanced placental oxygen uptake alleviates hypoxemic fetal stress. Appropriate fetal nutrition resumes. Cor placentale and severe intrauterine growth restriction are averted. Increased maternal cyclic nucleotide concentrations promote systemic vasodilatation so that blood pressures fall. Preemption of oxidative stress initiated by "consumptive" oxidation of nitric oxide stabilizes the vascular endothelium and corrects coagulopathy. Anti-inflammatory and immunosuppressant adenosine 3'5'-cyclic monphosphate offsets the extreme gestational inflammatory response. Cellular injury and multi-organ damage are prevented. One tablet a day of the new long acting phosphodiesterase-5 inhibitor, tadalafil (half life of 17.5 h) theoretically should allow a preterm pregnancy affected by preeclampsia to continue safely. Selective monitoring of vital organ functions guards against life-threatening maternal complications. Regular biophysical profiling warns the obstetrician of impending fetal compromise. Fetal growth and vital organ maturation can continue. As a result workloads imposed upon neonatal intensivists will lighten. Parental anxiety and concern will be allayed. The cost of treating preeclamptic mothers and their extremely low birth weight infants will decrease. Money saved by midwifery services in poorer states can be used to pay for better prenatal care. Severe preeclampsia/eclampsia will be less common. Maternal and perinatal morbidity and mortality will be reduced. Because the human immunodeficiency virus often infects individuals at a workforce eligible age, the global acquired immunodeficiency syndrome pandemic has already brought many nations to the brink of economic ruin. Potentially productive lives saved for the future will help restore them fiscally.


Asunto(s)
Modelos Biológicos , Insuficiencia Multiorgánica/enzimología , Insuficiencia Multiorgánica/prevención & control , Hidrolasas Diéster Fosfóricas/efectos de los fármacos , Hidrolasas Diéster Fosfóricas/metabolismo , Preeclampsia/tratamiento farmacológico , Preeclampsia/metabolismo , 3',5'-GMP Cíclico Fosfodiesterasas , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 5 , Inhibidores Enzimáticos/administración & dosificación , Femenino , Humanos , Insuficiencia Multiorgánica/etiología , Óxido Nítrico/metabolismo , Placenta/efectos de los fármacos , Placenta/metabolismo , Preeclampsia/complicaciones , Embarazo , Resultado del Tratamiento
18.
FASEB J ; 18(7): 854-6, 2004 May.
Artículo en Inglés | MEDLINE | ID: mdl-15001560

RESUMEN

Carbon monoxide (CO) has recently emerged as having potent cytoprotective properties; the mechanisms underlying these effects, however, are just beginning to be elucidated. In a rat model of lipopolysaccharide (LPS)-induced multiorgan failure, we demonstrate that exposure to a low concentration of CO for only 1 h imparts a potent defense against lethal endotoxemia and effectively abrogates the inflammatory response. Exposure to CO leads to long-term survival of >80% of animals vs. 20% in controls. In the lung, CO suppressed LPS-induced lung alveolitis and associated edema formation, while in the liver, it reduced expression of serum alanine aminotransferase, a marker of liver injury. This protection appears to be based in part on different mechanisms in the lung and liver in that CO had reciprocal effects on LPS-induced expression of iNOS and NO production, important mediators in the response to LPS. CO prevented the up-regulation of iNOS and NO in the lung while augmenting expression of iNOS and NO in the liver. Studies of primary lung macrophages and hepatocytes in vitro revealed a similar effect; CO inhibited LPS-induced cytokine production in lung macrophages while reducing LPS-induced iNOS expression and nitrite accumulation and protected hepatocytes from apoptosis while augmenting iNOS expression. Although it is unclear to which extent these changes in iNOS contribute to the cytoprotection conferred by CO, it is fascinating that in each organ CO influences iNOS in a manner known to be protective in that organ: NO is therapeutic in the liver while it is damaging in the lung.


Asunto(s)
Monóxido de Carbono/farmacología , Hígado/enzimología , Pulmón/enzimología , Óxido Nítrico Sintasa/fisiología , Choque Séptico/prevención & control , Animales , Apoptosis/efectos de los fármacos , Líquido del Lavado Bronquioalveolar , Células Cultivadas/efectos de los fármacos , Células Cultivadas/enzimología , Quimiotaxis de Leucocito/efectos de los fármacos , Citocinas/sangre , Citocinas/metabolismo , Inducción Enzimática/efectos de los fármacos , Hemo Oxigenasa (Desciclizante)/biosíntesis , Hemo-Oxigenasa 1 , Hepatocitos/citología , Hepatocitos/efectos de los fármacos , Hepatocitos/enzimología , Lipopolisacáridos/farmacología , Lipopolisacáridos/toxicidad , Activación de Macrófagos/efectos de los fármacos , Macrófagos Alveolares/efectos de los fármacos , Macrófagos Alveolares/enzimología , Macrófagos Alveolares/metabolismo , Masculino , Insuficiencia Multiorgánica/enzimología , Insuficiencia Multiorgánica/etiología , Insuficiencia Multiorgánica/prevención & control , FN-kappa B/fisiología , Óxido Nítrico/fisiología , Óxido Nítrico Sintasa/biosíntesis , Óxido Nítrico Sintasa de Tipo II , Especificidad de Órganos , Ratas , Ratas Sprague-Dawley , Choque Séptico/complicaciones , Choque Séptico/enzimología , Factor de Necrosis Tumoral alfa/farmacología
19.
Rev. Fac. Med. (Bogotá) ; 50(1): 26-35, ene.-mar. 2002. tab
Artículo en Español | LILACS | ID: lil-424571

RESUMEN

Se revisa el estado actual del conocimiento con respecto al papel fisiológico de las fosfolipasas A2, su clasificación funcional y molecular. Las PLA2 son enzimas que hidrolizan los ácidos grasos de membrana y llevan a la producción de derivados del ácido araquidónico entre otros. Se describen una serie de procesos patológicos en los cuales se encuentran involucradas. De otra parte se presentan los inhibidores específicos para cada una de las familias de PLA2 y su posible utilización terapéutica. Las PLA2 son enzimas implicadas en procesos inflamatorios, en acciones enzimáticas que deterioran varios sistemas y en el proceso de transducción de señal intracelular. El potencial de intervención con fines de tratamiento es bastante amplio y los inhibidores diseñados en los últimos años han sido muy específicos ya que han tenido en cuenta las particularidades estructurales de cada familia de PLA2, las cuales hacen que tengan funciones muy diferentes entre cada una de ellas. Se pueden augurar la aparición de nuevos tratamientos para enfermedades de tipo metabólico como la diabetes, inflamatorios como la sepsis, enfermedades autoinmunes e infecciones por la inhibición de procesos de invasión de organismos intracelulares obligatorios


Asunto(s)
Fibrosis Quística/enzimología , Insuficiencia Multiorgánica/enzimología , Pancreatitis Aguda Necrotizante , Fosfolipasas A
20.
Res Commun Mol Pathol Pharmacol ; 109(3-4): 159-64, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11758647

RESUMEN

Changes in the blood levels of type II phospholipase A2 (PLA2) were investigated over time in patients with acute pancreatitis from an early stage after manifestation of the disease. The serum level of type II PLA2 at the first examination and the maximum level during the course of illness were both correlated with the severity of the disease. Serum levels of type II PLA2 were significantly higher in patients with acute pancreatitis complicated by multiple organ failure (349.1 +/- 146.6 ng/ml) than in those with acute pancreatitis not complicated by multiple organ failure (66.9 +/- 50.1 ng/ml). The serum levels of type II PLA2 were also significantly higher in patients who eventually died (316.8 +/- 150.5 ng/ml) than in those who survived (148.9 +/- 167.9 ng/ml). There was a significant correlation between the serum levels of type II PLA2 and those of TNF-alpha during the course of illness (r = 0.8037, p < 0.0001). The serum levels of type II PLA2 reliably reflected the severity of acute pancreatitis even in the early stages of the disease. These results suggest that type II PLA2 may be closely involved in the pathophysiology of acute pancreatitis.


Asunto(s)
Pancreatitis/enzimología , Fosfolipasas A/sangre , Enfermedad Aguda , Biomarcadores , Femenino , Humanos , Masculino , Persona de Mediana Edad , Insuficiencia Multiorgánica/enzimología , Insuficiencia Multiorgánica/patología , Pancreatitis/complicaciones , Pancreatitis/patología , Fosfolipasas A2 , Sobrevida , Factor de Necrosis Tumoral alfa/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA